Idiopathic pulmonary fibrosis (IPF) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Idiopathic pulmonary fibrosis (IPF)

"Idiopathic pulmonary fibrosis (IPF) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Idiopathic pulmonary fibrosis (IPF) is a serious chronic disease that affects the tissue surrounding the air sacs, or alveoli, in the lungs. This condition occurs when that lung tissue becomes thick and stiff for unknown reasons. Over time, these changes can cause permanent scarring in the lungs, called fibrosis, which makes it progressively more difficult to breathe. Usually the breathlessness of IPF first appears during exercise. Breathlessness can affect day-to-day activities such as showering, climbing stairs, getting dressed and eating. As scarring in the lungs gets worse, breathlessness may prevent all activities. About 85% of people with IPF have a chronic cough that has lasts longer than 8 weeks. This is often a dry cough, but some people may also cough up sputum or phlegm.

The exact, underlying cause of IPF is not fully understood. Different factors, including immunologic, environmental, and genetic ones, are thought to play a role in the development of the disorder.  The strongest risk factor, accounting for 30% of risk of developing IPF, is a variation in the MUC5B gene that results in more mucus production in the smallest airways in the lung (respiratory bronchioles). Certain affected individuals are genetically predisposed (susceptible) to developing IPF following such exposures described above. A person who is genetically predisposed to a disorder carries a gene (or genes) for the disease, but it may not be expressed unless it is triggered or “activated” under certain circumstances, such as due to particular environmental or immunologic factors. A number of genes have implicated in the development of IPF and aggregate account for 35-40% of the risk of developing IPF. These genes include genes that preserve host defense, cell survival, and cell-cell interactions.

KOLs insights of Idiopathic pulmonary fibrosis (IPF) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

The epidemiological data, presented by the National Institute of Health (NIH), estimated that IPF has a prevalence of 13 to 20 per 100,000 people worldwide. Moreover, about 100,000 individuals are affected in the United States and nearly 30,000 to 40,000 new cases are diagnosed every year. Also, the overall prevalence of IPF in men and women was 20.2 per 100,000 and 13.2 per 100,000 respectively. The indication usually affects people between the ages of 50 and 70.

Competitive landscape of Idiopathic pulmonary fibrosis (IPF) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Idiopathic pulmonary fibrosis (IPF) Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Idiopathic pulmonary fibrosis (IPF) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        GB0139        Galecto Biotech AB        Phase 2

2        tralokinumab cohort        AstraZeneca        Phase 2

3        Nalbuphine ER        Trevi Therapeutics        Phase 2

4        SAR156597        Sanofi        Phase 2

5        Pamrevlumab        FibroGen        Phase 3

6        TRK-250        Toray Industries, Inc        Phase 1

7        VAY736        Novartis Pharmaceuticals        Phase 2

8        PRM-151        Hoffmann-La Roche        Phase 3

9        GLPG1690 600 mg QD        Galapagos NV        Phase 2

10        ART-123        Asahi Kasei Pharma Corporation        Phase 3

11        ORIN1001        Orinove, Inc.        Phase 1

12        Jaktinib Dihydrochloride Monohydrate        Suzhou Zelgen Biopharmaceuticals Co.,Ltd        Phase 2

13        Ifenprodil        Algernon Pharmaceuticals        Phase 2

14        PLN-74809        Pliant Therapeutics, Inc.        Phase 2

15        GSK2126458        GlaxoSmithKline        Phase 1

16        BBT-877        Bridge Biotherapeutics, Inc.        Phase 1

17        HEC585        Sunshine Lake Pharma Co., Ltd.        Phase 1

18        KD025        Kadmon Corporation, LLC        Phase 2

19        BI 1015550        Boehringer Ingelheim        Phase 2

20        Gefapixant        Afferent Pharmaceuticals, Inc.        Phase 2

21        BMS-986020        Bristol-Myers Squibb        Phase 2

22        PBI4050        Liminal BioSciences Ltd.        Phase 2

23        C21        Vicore Pharma AB        Phase 2

24        BG00011        Biogen        Phase 2

25        tipelukast        MediciNova        Phase 2

26        Tyvaso® (treprostinil)        United Therapeutics        Phase 3

27        TD-1058        Theravance Biopharma        Phase 1

28        ND-L02-s0201        Nitto Denko Corporation        Phase 2

29        Lung stem cells        Regend Therapeutics        Phase 2

30        fostair        Chiesi Farmaceutici S.p.A.        Phase 2

31        DWN12088        Daewoong Pharmaceutical Co. LTD.        Phase 1

32        GBT440        Global Blood Therapeutics        Phase 2

33        MG-S-2525        Metagone Biotech Inc.        Phase 1

34        Inhaled Nitric Oxide        Geno LLC        Phase 2

35        CC-90001        Celgene        Phase 2

36        ZSP1603        Guangdong Zhongsheng Pharmaceutical Co., Ltd.        Phase 1

37        inhaled Nitric Oxide        Bellerophon        Phase 1

38        ZL-2102        Zai Lab Pty. Ltd.        Phase 1"